Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMOQ9H1)

Drug Name
Tremelimumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Approved [1]
Malignant mesothelioma 2C26.0 Phase 3 [2]
Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
Cross-matching ID
TTD Drug ID
DMOQ9H1

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Modulator [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cytotoxic T-lymphocyte protein 4 (CTLA-4) DTT CTLA4 4.684 5.333 3.954 2.293
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hepatocellular carcinoma
ICD Disease Classification 2C12.02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytotoxic T-lymphocyte protein 4 (CTLA-4) DTT CTLA4 2.73E-01 0.02 0.05
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761289.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8462).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).